报价延迟最少15分钟:2026/04/21 21:24 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.28/--
|
|
企业价值
133.35M
|
| 资产负债 |
|
每股账面净值
4.60
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
16.12M
|
|
每股收益
0.26
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa. |
